Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7479)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Oct 15, 2019 (publication date) through Nov 20, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Personeni N, Pressiani T, Bozzarelli S, Rimassa L. Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(10): 788-803 [PMID: 31662820 DOI: 10.4251/wjgo.v11.i10.788] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v11/i10/788.htm |
| Number | Citing Articles |
| 1 |
Keyur Patel, Ryan Lamm, Peter Altshuler, Hien Dang, Ashesh P. Shah. Hepatocellular Carcinoma—The Influence of Immunoanatomy and the Role of Immunotherapy. International Journal of Molecular Sciences 2020; 21(18): 6757 doi: 10.3390/ijms21186757
|
| 2 |
Yanping Tang, Ji Cao, Zhengmin Cai, Huihua An, Yuqun Li, Yan Peng, Ni Chen, Anqiang Luo, Hao Tao, Kezhi Li. Epigallocatechin gallate induces chemopreventive effects on rats with diethylnitrosamine‑induced liver cancer via inhibition of cell division cycle 25A. Molecular Medicine Reports 2020; doi: 10.3892/mmr.2020.11463
|
| 3 |
Binquan Wu, Amin Li, Yinci Zhang, Xueke Liu, Shuping Zhou, Huaiyong Gan, Shiyu Cai, Yong Liang, Xiaolong Tang. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles. Expert Opinion on Drug Delivery 2020; 17(4): 573 doi: 10.1080/17425247.2020.1730809
|
| 4 |
Valeria De Gaetano, Maria Pallozzi, Lucia Cerrito, Francesco Santopaolo, Leonardo Stella, Antonio Gasbarrini, Francesca Romana Ponziani. Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives. Cancers 2024; 16(7): 1388 doi: 10.3390/cancers16071388
|
| 5 |
Neehar D. Parikh, Allicia Girvan, Joshua Coulter, Jonathon Gable, Jiat Ling Poon, Sangmi Kim, Anindya Chatterjee, Marco Boeri. Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study. BMC Cancer 2023; 23(1) doi: 10.1186/s12885-022-10388-8
|
| 6 |
Jingquan Huang, Qiulin Wu, David A. Geller, Yihe Yan. Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC). Journal of Translational Medicine 2023; 21(1) doi: 10.1186/s12967-023-04716-0
|
| 7 |
Alessandro Rizzo, Margherita Nannini, Marco Novelli, Angela Dalia Ricci, Valerio Di Scioscio, Maria Abbondanza Pantaleo. Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology 2020; 12 doi: 10.1177/1758835920936932
|
| 8 |
Antonella Cammarota, Valentina Zanuso, Antonio D’Alessio, Tiziana Pressiani, Nicola Personeni, Lorenza Rimassa. Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials. Expert Opinion on Investigational Drugs 2022; 31(4): 401 doi: 10.1080/13543784.2022.2032641
|
| 9 |
Hui Li. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Review of Gastroenterology & Hepatology 2021; 15(3): 217 doi: 10.1080/17474124.2021.1842732
|